Table 5.
Results of the statistical analyses.
| Prevalence of hyponatremia | |||||
|---|---|---|---|---|---|
| Subgroups | RR | 95% CI | P value | Heterogeneity (I ∧ 2) |
P
value of heterogeneity |
| SCLC | 0.24 | [0.18; 0.30] | NS p = 0.425 |
96.56% | <0.001 <0.001 |
| NSCLC | 0.27 | [0.17; 0.39] | 98.57% | ||
| male vs. female | 1.15 | [0.86; 1.53] | NS p = 0.354 |
75.40% | <0.001 |
| <60 years vs. ≥60 years | 0.97 | [0.80; 1.19] | NS p = 0.773 |
0.00% | 0.657 |
| ECOG ≤ 1 vs. ECOG>1 | 0.80 | [0.59; 1.09] | NS p = 0.161 |
70.10% | 0.001 |
| LD vs. ED stage | 1.17 | [0.60; 2.28] | NS p = 0.655 |
87.8% | <0.001 |
| Overall survival rates | |||||
| Hyponatremic vs. Normonatremic patients: | |||||
| 10 months | 0.59 | [0.47; 0.74] | <0.001 | 81.1% | <0.001 |
| 20 months | 0.44 | [0.33; 0.59] | <0.001 | 40.5% | 0.109 |
| Hyponatremic SCLC vs. NSCLC patients at 10 months: | |||||
| SCLC | 0.42 | [0.27; 0.57] | <0.001 | 92.72% | <0.001 |
| NSCLC | 0.27 | [0.12; 0.44] | <0.001 | - | - |
| Corrected vs. Uncorrected hyponatremic patients: | |||||
| 10 months | 1.83 | [1.37; 2.44] | <0.001 | 0.0% | 0.775 |
| 20 months | 2.65 | [0.94; 7.50] | 0.067 | 23.3% | 0.271 |
ES, effect size; RR, risk ratio; CI, confidence interval; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group performance status; LD, limited disease; ED, extensive disease.